{"issuance_frequency":"","notes_translated":{"fr":"Le document d'orientation fournit aux candidats qui souhaitent obtenir l'autorisation de mener des essais cliniques sur les médicaments COVID-19, en particulier autour des lignes directrices et du processus de demande.","en":"Guidance document provides applicants seeking authorization to conduct COVID-19 drug clinical trials specifically around the applications guidelines and process."},"issn":"","imso_approval":"true","isbn":"","creator":"","org_section":{"fr":"","en":""},"jurisdiction":"federal","private":false,"maintainer_email":"open-ouvert@tbs-sct.gc.ca","num_tags":0,"edition":"","frequency":"as_needed","data_series_issue_identification":{"fr":"","en":""},"contributor":{"fr":"","en":""},"maintainer":null,"ready_to_publish":"true","id":"eb5b2f9e-5ea1-485d-80cb-658c374e7a84","metadata_created":"2021-05-28T16:20:58.295575","subject":["health_and_safety"],"pspc_identification_number":"","metadata_modified":"2021-05-28T16:20:58.295582","author":null,"author_email":null,"geographic_region":[],"portal_release_date":"2021-05-28","digital_object_identifier":"","state":"active","version":null,"keywords":{"fr":["orientation","document","ordonnance provisoire","coronavirus","COVID-19","essai clinique","médicament","réglementation","phases d'essai clinique","autorisation de médicament","approbation de médicament"],"en":["guidance","document","Interim Order","coronavirus","COVID-19","clinical trial","drug","regulations","clinical trial phases","drug authorization","drug approval"]},"relationships_as_object":[],"creator_user_id":"2dc5a12f-2a6f-4822-8514-165ea6bb05d9","title_translated":{"fr":"Lignes directrices sur les demandes d’essais cliniques de médicaments au titre de l’arrêté d’urgence : Aperçu","en":"Guidance on applications for drug clinical trials under the interim order: Overview"},"type":"info","resources":[{"cache_last_updated":null,"unique_identifier":"","package_id":"eb5b2f9e-5ea1-485d-80cb-658c374e7a84","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"9576f652-5764-420d-8e01-76bbe4ee8451","related_relationship":"","name_translated":{"fr":"Lignes directrices sur les demandes d’essais cliniques de médicaments au titre de l’arrêté d’urgence : Aperçu","en":"Guidance on applications for drug clinical trials under the interim order: Overview"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance on applications for drug clinical trials under the interim order: Overview","language":["en"],"created":"2021-05-28T16:20:58.388000","url":"https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/clinical-trials-interim-order-2-drug-guidance.html","last_modified":null,"position":0,"revision_id":"9bfb9079-a7db-499f-be69-f299d3518a00","resource_type":"publication"},{"cache_last_updated":null,"unique_identifier":"","package_id":"eb5b2f9e-5ea1-485d-80cb-658c374e7a84","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"fdd77377-2e6d-4799-a8da-84b1d1eb7c1f","related_relationship":"","name_translated":{"fr":"Lignes directrices sur les demandes d’essais cliniques de médicaments au titre de l’arrêté d’urgence : Aperçu","en":"Guidance on applications for drug clinical trials under the interim order: Overview"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance on applications for drug clinical trials under the interim order: Overview","language":["fr"],"created":"2021-05-28T16:20:58.388006","url":"https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/covid19-industrie/medicaments-vaccins-traitements/essais-cliniques-arrete-urgence-2-medicaments-directrices.html","last_modified":null,"position":1,"revision_id":"9bfb9079-a7db-499f-be69-f299d3518a00","resource_type":"publication"},{"cache_last_updated":null,"unique_identifier":"","package_id":"eb5b2f9e-5ea1-485d-80cb-658c374e7a84","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"136486f2-5a2c-4349-b350-70e429da317f","related_relationship":"","name_translated":{"fr":"Lignes directrices sur les demandes d’essais cliniques de médicaments au titre de l’arrêté d’urgence : Lignes directrices et processus de demande","en":"Guidance on applications for drug clinical trials under the interim order: Application guidelines and process"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance on applications for drug clinical trials under the interim order: Application guidelines and process","language":["en"],"created":"2021-05-28T16:20:58.388008","url":"https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/clinical-trials-interim-order-2-drug-guidance/applications.html","last_modified":null,"position":2,"revision_id":"9bfb9079-a7db-499f-be69-f299d3518a00","resource_type":"publication"},{"cache_last_updated":null,"unique_identifier":"","package_id":"eb5b2f9e-5ea1-485d-80cb-658c374e7a84","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"8fd71727-c9cb-4321-8a15-8c4241ea88c1","related_relationship":"","name_translated":{"fr":"Lignes directrices sur les demandes d’essais cliniques de médicaments au titre de l’arrêté d’urgence : Exigences générales","en":"Guidance on applications for drug clinical trials under the interim order: General requirements"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance on applications for drug clinical trials under the interim order: General requirements","language":["en"],"created":"2021-05-28T16:20:58.388010","url":"https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/clinical-trials-interim-order-2-drug-guidance/requirements.html","last_modified":null,"position":3,"revision_id":"9bfb9079-a7db-499f-be69-f299d3518a00","resource_type":"publication"},{"cache_last_updated":null,"unique_identifier":"","package_id":"eb5b2f9e-5ea1-485d-80cb-658c374e7a84","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"74d191a0-24b7-44c9-aab9-f3d13b9b4b7f","related_relationship":"","name_translated":{"fr":"Lignes directrices sur les demandes d’essais cliniques de médicaments au titre de l’arrêté d’urgence : Exigences générales","en":"Guidance on applications for drug clinical trials under the interim order: General requirements"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance on applications for drug clinical trials under the interim order: General requirements","language":["fr"],"created":"2021-05-28T16:20:58.388012","url":"https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/covid19-industrie/medicaments-vaccins-traitements/essais-cliniques-arrete-urgence-2-medicaments-directrices/exigences.html","last_modified":null,"position":4,"revision_id":"9bfb9079-a7db-499f-be69-f299d3518a00","resource_type":"publication"},{"cache_last_updated":null,"unique_identifier":"","package_id":"eb5b2f9e-5ea1-485d-80cb-658c374e7a84","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"0f73f47a-b9a7-499f-900b-86a8a5f63338","related_relationship":"","name_translated":{"fr":"Lignes directrices sur les demandes d’essais cliniques de médicaments au titre de l’arrêté d’urgence : Exigences supplémentaires","en":"Guidance on applications for drug clinical trials under the interim order: Additional requirements"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance on applications for drug clinical trials under the interim order: Additional requirements","language":["en"],"created":"2021-05-28T16:20:58.388014","url":"https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/clinical-trials-interim-order-2-drug-guidance/additional-requirements.html","last_modified":null,"position":5,"revision_id":"9bfb9079-a7db-499f-be69-f299d3518a00","resource_type":"publication"},{"cache_last_updated":null,"unique_identifier":"","package_id":"eb5b2f9e-5ea1-485d-80cb-658c374e7a84","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"95ea3109-f700-43ee-9162-331ff8ccf5e0","related_relationship":"","name_translated":{"fr":"Lignes directrices sur les demandes d’essais cliniques de médicaments au titre de l’arrêté d’urgence : Exigences supplémentaires","en":"Guidance on applications for drug clinical trials under the interim order: Additional requirements"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance on applications for drug clinical trials under the interim order: Additional requirements","language":["fr"],"created":"2021-05-28T16:20:58.388016","url":"https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/covid19-industrie/medicaments-vaccins-traitements/essais-cliniques-arrete-urgence-2-medicaments-directrices/exigences-supplementaires.htm","last_modified":null,"position":6,"revision_id":"9bfb9079-a7db-499f-be69-f299d3518a00","resource_type":"publication"},{"cache_last_updated":null,"unique_identifier":"","package_id":"eb5b2f9e-5ea1-485d-80cb-658c374e7a84","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"8f2dc21e-604a-44dd-80c4-a09d1f9285af","related_relationship":"","name_translated":{"fr":"Lignes directrices sur les demandes d’essais cliniques de médicaments au titre de l’arrêté d’urgence : Exigences faisant suite à l’autorisation","en":"Guidance on applications for drug clinical trials under the interim order: Post-authorization requirements"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance on applications for drug clinical trials under the interim order: Post-authorization requirements","language":["en"],"created":"2021-05-28T16:20:58.388018","url":"https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/clinical-trials-interim-order-2-drug-guidance/post-authorization.html","last_modified":null,"position":7,"revision_id":"9bfb9079-a7db-499f-be69-f299d3518a00","resource_type":"publication"},{"cache_last_updated":null,"unique_identifier":"","package_id":"eb5b2f9e-5ea1-485d-80cb-658c374e7a84","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"efb035bf-b5b7-40a3-a045-d6df0b4fdae6","related_relationship":"","name_translated":{"fr":"Lignes directrices sur les demandes d’essais cliniques de médicaments au titre de l’arrêté d’urgence : Exigences faisant suite à l’autorisation","en":"Guidance on applications for drug clinical trials under the interim order: Post-authorization requirements"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance on applications for drug clinical trials under the interim order: Post-authorization requirements","language":["fr"],"created":"2021-05-28T16:20:58.388020","url":"https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/covid19-industrie/medicaments-vaccins-traitements/essais-cliniques-arrete-urgence-2-medicaments-directrices/suite-autorisation.html","last_modified":null,"position":8,"revision_id":"9bfb9079-a7db-499f-be69-f299d3518a00","resource_type":"publication"},{"cache_last_updated":null,"unique_identifier":"","package_id":"eb5b2f9e-5ea1-485d-80cb-658c374e7a84","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"7cf080fa-6f8f-4df9-a3ce-f64a476f9529","related_relationship":"","name_translated":{"fr":"Lignes directrices sur les demandes d’autorisation de mener un essai clinique sur un médicament au titre de l’arrêté d’urgence : Avec qui communiquer","en":"Guidance on applications for drug clinical trials under the interim order: Who to contact"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance on applications for drug clinical trials under the interim order: Who to contact","language":["en"],"created":"2021-05-28T16:20:58.388022","url":"https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/clinical-trials-interim-order-2-drug-guidance/contact.html","last_modified":null,"position":9,"revision_id":"9bfb9079-a7db-499f-be69-f299d3518a00","resource_type":"publication"},{"cache_last_updated":null,"unique_identifier":"","package_id":"eb5b2f9e-5ea1-485d-80cb-658c374e7a84","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"7ebee064-1fd4-47ca-a6f0-016da251affb","related_relationship":"","name_translated":{"fr":"Demandes d'essais cliniques de médicaments et d'instruments médicaux liés à la COVID-19 au titreau titre de l'arrêté d'urgence : Avis de mise à jour des lignes directrices","en":"Applications for COVID-19 drug and medical device clinical trials under the interim order: Notice of updated guidance documents"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Applications for COVID-19 drug and medical device clinical trials under the interim order: Notice of updated guidance documents","language":["fr"],"created":"2021-05-28T16:20:58.388023","url":"https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/covid19-industrie/medicaments-vaccins-traitements/essais-cliniques-arrete-urgence-2-medicaments-directrices/communiquer.html","last_modified":null,"position":10,"revision_id":"9bfb9079-a7db-499f-be69-f299d3518a00","resource_type":"publication"}],"place_of_publication":[],"num_resources":11,"tags":[],"spatial":"","collection":"publication","org_title_at_publication":{"fr":"Santé Canada","en":"Health Canada"},"date_published":"2021-04-28 00:00:00","issuance":"","groups":[],"license_id":"ca-ogl-lgo","data_series_name":{"fr":"","en":""},"relationships_as_subject":[],"license_title":"Open Government Licence - Canada","restrictions":"unrestricted","organization":{"description":"","created":"2016-09-23T17:25:33.001625","title":"Health Canada | Santé Canada","name":"hc-sc","is_organization":true,"state":"active","image_url":"","revision_id":"6a0471e8-36e5-4217-8f72-563c83e6465a","type":"organization","id":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","approval_status":"approved"},"name":"eb5b2f9e-5ea1-485d-80cb-658c374e7a84","isopen":false,"additional_notes":{"fr":"","en":""},"departmental_identification_number":"","notes":"Guidance document provides applicants seeking authorization to conduct COVID-19 drug clinical trials specifically around the applications guidelines and process.","owner_org":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","program_page_url":{"fr":"","en":""},"url":null,"audience":[],"gc_catalogue_number":"","license_url":"http://open.canada.ca/en/open-government-licence-canada","series_publication_dates":{"fr":"","en":""},"title":"Guidance on applications for drug clinical trials under the interim order: Overview","revision_id":"9bfb9079-a7db-499f-be69-f299d3518a00"}